专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007071455B1 SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS 审中-公开
标题翻译：磺胺嘧啶取代的嘧啶类化合物，它们的制备和用作药物
公开(公告)号：WO2007071455B1
公开(公告)日：2007-08-30
申请号：PCT/EP2006012634
申请日：2006-12-19
申请人： SCHERING AG , LUECKING ULRICH , NGUYEN DUY , VON BONIN ARNE , VON AHSEN OLIVER , KRUEGER MARTIN , BRIEM HANS , KETTSCHAU HANS , PRIEN OLAF , MENGEL ANNE , KROLIKIEWICZ KONRAD , BOEMER ULF , BOTHE ULRICH , HARTUNG INGO
发明人： LUECKING ULRICH , NGUYEN DUY , VON BONIN ARNE , VON AHSEN OLIVER , KRUEGER MARTIN , BRIEM HANS , KETTSCHAU HANS , PRIEN OLAF , MENGEL ANNE , KROLIKIEWICZ KONRAD , BOEMER ULF , BOTHE ULRICH , HARTUNG INGO
IPC分类号： C07D239/47 , A61K31/505 , A61K31/506 , A61P29/00 , A61P35/00 , A61P37/00 , C07D239/48 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D417/04
CPC分类号： C07D239/28 , C07D239/47 , C07D239/48 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/14 , C07D413/04 , C07D417/04
摘要： The invention relates to sulfoximine-substituted pyrimidines of the general Formula (I) processes for the preparation thereof and their use as kinase inhibitors for treating for example cancer or inflammation.
摘要翻译：本发明涉及通式（I）的亚磺酰亚胺取代的嘧啶的制备方法及其作为激酶抑制剂用于治疗例如癌症或炎症的用途。

2. 发明申请

WO2008155140A8 ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS 审中-公开
标题翻译： ALKYNYLPYRIMIDINES作为TIE2激酶抑制剂
公开(公告)号：WO2008155140A8
公开(公告)日：2009-12-23
申请号：PCT/EP2008005215
申请日：2008-06-19
申请人： BAYER SCHERING PHARMA AG , HARTUNG INGO , BOTHE ULRICH , KETTSCHAU GEORG , LUECKING ULRICH , MENGEL ANNE , KRUEGER MARTIN , THIERAUCH KARL-HEINZ , LIENAU PHILIP , BOEMER ULF
发明人： HARTUNG INGO , BOTHE ULRICH , KETTSCHAU GEORG , LUECKING ULRICH , MENGEL ANNE , KRUEGER MARTIN , THIERAUCH KARL-HEINZ , LIENAU PHILIP , BOEMER ULF
IPC分类号： C07D239/48 , A61K31/495 , A61P29/00 , A61P35/00 , C07D401/06 , C07D403/06
CPC分类号： C07D239/48 , C07D401/06 , C07D403/06
摘要： The invention relates to alkynylpyrimidines according to the general formula (I) in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.
摘要翻译：本发明涉及根据通式（I）的炔基嘧啶，其中A，R 1，R 2，R 3，R 4，R 5和R 6如权利要求中所定义，包括所述炔基嘧啶的药物组合物，制备所述炔基嘧啶的方法，以及其用于制备用于治疗失调的血管生长疾病或伴随血管生长紊乱的疾病的药物组合物的用途，其中所述化合物有效地干扰Tie2和VEGFR2信号传导。

3. 发明申请

WO2009074247A8 NOVEL 2-ARYL-THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT 审中-公开
标题翻译： NEW 2-芳基噻唑-4-羧酸酰胺衍生物，生产和使用AS DRUGS
公开(公告)号：WO2009074247A8
公开(公告)日：2010-07-15
申请号：PCT/EP2008010188
申请日：2008-12-02
申请人： BAYER SCHERING PHARMA AG , BOTHE ULRICH , VON BONIN ARNE , NGUYEN DUY , BOEMER ULF , GUENTHER JUDITH
发明人： BOTHE ULRICH , VON BONIN ARNE , NGUYEN DUY , BOEMER ULF , GUENTHER JUDITH
IPC分类号： C07D277/32 , A61K31/425 , A61P37/02 , C07D417/12 , C07D417/14 , C07D495/04
CPC分类号： C07D277/56 , C07D417/04 , C07D417/12 , C07D417/14 , C07D495/04
摘要： The invention relates to 2-aryl thiazole-4-carboxamide derivatives of formula (I), the use thereof as a medicament for treating various diseases, and methods for the production thereof.
摘要翻译：本发明涉及式（I），它们的作为各种疾病的治疗药物的用途的2-芳基噻-4-羧酸酰胺衍生物，以及它们的制备方法。

4. 发明申请

WO2006136461A3 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS 审中-公开
标题翻译：非甾体孕激素受体调节剂
公开(公告)号：WO2006136461A3
公开(公告)日：2007-03-15
申请号：PCT/EP2006006531
申请日：2006-06-22
申请人： SCHERING AG , HILLISCH ALEXANDER , BOTHE ULRICH , KAUFMANN GUENTER , SOBEK LOTHAR , FUHRMANN ULRIKE , DROESCHER PETER , SCHMEES NORBERT , SCHWEDE WOLFGANG , MOELLER CARSTEN , SCHMIDT ANJA
发明人： HILLISCH ALEXANDER , BOTHE ULRICH , KAUFMANN GUENTER , SOBEK LOTHAR , FUHRMANN ULRIKE , DROESCHER PETER , SCHMEES NORBERT , SCHWEDE WOLFGANG , MOELLER CARSTEN , SCHMIDT ANJA
IPC分类号： C07D413/12 , A61K31/536 , A61P5/34 , C07D265/02
CPC分类号： C07D413/12 , C07D265/02
摘要： The present invention relates to non-steroidal progesterone receptor modulators of the general formula (I), a process for their preparation, the use of the progesterone receptor modulators for producing medicaments, and pharmaceutical compositions comprising these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional (bleeding )and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.
摘要翻译：本发明涉及通式（I）的非甾体孕激素受体调节剂，其制备方法，孕酮受体调节剂用于生产药物的用途，以及包含这些化合物的药物组合物。根据本发明的化合物适用于治疗和预防妇科疾病如子宫内膜异位症，子宫平滑肌瘤，功能障碍（出血）和痛经，以及用于治疗和预防激素依赖性肿瘤并用于女性生育控制并用于激素替代疗法。

5. 发明申请

WO2006003013B1 NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17ß-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1 审中-公开
标题翻译： NEW 2-取代的雌-1,3,5（10） - 三烯-17-酮作为17-β-羟类固醇脱氢酶类型1抑制剂
公开(公告)号：WO2006003013B1
公开(公告)日：2006-08-31
申请号：PCT/EP2005007315
申请日：2005-07-04
申请人： SCHERING AG , HILLISCH ALEXANDER , REGENHARDT WILKO , GEGE CHRISTIAN , PETERS OLAF , BOTHE ULRICH , ADAMSKI JERZY , MOELLER GABRIELE , ROSINUS ANDREA , ELGER WALTER , SCHNEIDER BIRGITT
发明人： HILLISCH ALEXANDER , REGENHARDT WILKO , GEGE CHRISTIAN , PETERS OLAF , BOTHE ULRICH , ADAMSKI JERZY , MOELLER GABRIELE , ROSINUS ANDREA , ELGER WALTER , SCHNEIDER BIRGITT
IPC分类号： C07J1/00 , A61K31/566 , A61P5/32 , C07J31/00 , C07J41/00 , C07J53/00
CPC分类号： C07J53/004 , A61K31/565 , A61K45/06 , C07J1/0059 , C07J31/003 , C07J41/0094 , A61K2300/00
摘要： The invention relates to novel 2-substituted estra-1,3,5(10)-trien-17-ones of formula (I), wherein R 2 is an C 1 -C 8 alkyl saturated or unsaturated group, an C 1 -C 5 -alkyloxy group, an aralkyl- or alkylaryl rest, an -O-C n F m H o rest, wherein n=1,2,3,4,5 or 6, m=1 and m = 2n+1, or a CH 2 XY group in which X is an oxygen atom and Y is an alkyl rest containing 1 to 4 carbon atoms, a halogen atom and a nitrile group, R 13 is a hydrogen atom or a methyl group, R 16 is a hydrogen or fluorine atom, Z is an oxygen or sulfur atom, each R 4 and R 6 independently of each other represents a or ß hydrogen atom, an C 1 -C 5 alkyl, C 1 -C 5 -alkyloxy, C 1 -C 5 -acyl or hydroxy group or an aralkyl- or alkylaryl rest, R 3 and R 4 represent together an oxygen atom, R 5 and R 6 represent together an oxygen atom, each R 7 and R 8 represents a hydrogen atom or together an oxygen atom, each R 7 and R 8 represents a hydrogen atom or together a CH 2 group. Pharmaceutically acceptable salts of said compounds, the production and use thereof in the form of drags which are usable for preventing and treating estrogen-dependent diseases and are influenced by inhibiting 17ß-hydroxysteroiddehydrogenase of type 1 are also disclosed.
摘要翻译：本发明涉及新的2-取代的雌-1,3,5（10） - 三烯-17-酮的通式（I），其中R ^{2 是饱和或不饱和的C _{1 < / SUB> -C _{8 烷基，一个C _{1 -C _{5 烷氧基，芳烷基或烷芳基，基团-O-C < 其中n = 1,2,3,4,5或6，m = 1，m = 2n + 1 ，或基团CH _{2 XY，其中X表示氧原子，Y是碳原子数为1〜4的烷基，卤素原子或腈基，R ^{13 氢原子或甲基，R ^{16 代表氢原子或氟原子，Z是氧或硫原子，R ^{3 和R ^{5 各自独立地为表示α-或β-位置氢原子，R ^{4 和R ^{6 各自独立地为α-或β-位置氢原子，C _{1 1 -C _{5 酰基，或羟基或芳烷基或烷芳基，R _{3 和R _{4 一起为氧原子，R _{5 和R _{6 一起为氧原子，R ^{7 和R ^{8 各自为氢原子或一起CH _{2 是一个基团，及其药学上可接受的盐，它们的制备和作为药物的雌激素依赖性疾病的预防和治疗为特征的抑制17-Hydroxysteroiddehydro-的使用 genase 1型影响。}}}}}}}}}}}}}}}}}}}}}

6. 发明申请

WO2006003013A3 NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17ß-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1 审中-公开
标题翻译： NEW 2-取代的雌-1,3,5（10） - 三烯-17-酮作为17-β-羟类固醇脱氢酶类型1抑制剂
公开(公告)号：WO2006003013A3
公开(公告)日：2006-06-22
申请号：PCT/EP2005007315
申请日：2005-07-04
申请人： SCHERING AG , HILLISCH ALEXANDER , REGENHARDT WILKO , GEGE CHRISTIAN , PETERS OLAF , BOTHE ULRICH , ADAMSKI JERZY , MOELLER GABRIELE , ROSINUS ANDREA , ELGER WALTER , SCHNEIDER BIRGITT
发明人： HILLISCH ALEXANDER , REGENHARDT WILKO , GEGE CHRISTIAN , PETERS OLAF , BOTHE ULRICH , ADAMSKI JERZY , MOELLER GABRIELE , ROSINUS ANDREA , ELGER WALTER , SCHNEIDER BIRGITT
IPC分类号： C07J1/00 , A61K31/566 , A61P5/32 , C07J31/00 , C07J41/00 , C07J53/00
CPC分类号： C07J53/004 , A61K31/565 , A61K45/06 , C07J1/0059 , C07J31/003 , C07J41/0094 , A61K2300/00
摘要： The invention relates to novel 2-substituted estra-1,3,5(10)-trien-17-ones of formula (I), wherein R 2 is an C 1 -C 8 alkyl saturated or unsaturated group, an C 1 -C 5 -alkyloxy group, an aralkyl- or alkylaryl rest, an -O-C n F m H o rest, wherein n=1,2,3,4,5 or 6, m=1 and m = 2n+1, or a CH 2 XY group in which X is an oxygen atom and Y is an alkyl rest containing 1 to 4 carbon atoms, a halogen atom and a nitrile group, R 13 is a hydrogen atom or a methyl group, R 16 is a hydrogen or fluorine atom, Z is an oxygen or sulfur atom, each R 4 and R 6 independently of each other represents a or ß hydrogen atom, an C 1 -C 5 alkyl, C 1 -C 5 -alkyloxy, C 1 -C 5 -acyl or hydroxy group or an aralkyl- or alkylaryl rest, R 3 and R 4 represent together an oxygen atom, R 5 and R 6 represent together an oxygen atom, each R 7 and R 8 represents a hydrogen atom or together an oxygen atom, each R 7 and R 8 represents a hydrogen atom or together a CH 2 group. Pharmaceutically acceptable salts of said compounds, the production and use thereof in the form of drags which are usable for preventing and treating estrogen-dependent diseases and are influenced by inhibiting 17ß-hydroxysteroiddehydrogenase of type 1 are also disclosed.
摘要翻译：本发明涉及新的2-取代的雌-1,3,5（10） - 三烯-17-酮的通式（I），其中R ^{2 是饱和或不饱和的C _{1 < / SUB> -C _{8 烷基，一个C _{1 -C _{5 烷氧基，芳烷基或烷芳基，基团-O-C < SUB>名词˚F_{米ħ_{0 ，其中n = 1,2,3,4,5或6中，m = 1且m = 2n + 1个，或基团CH _{2 XY，其中X表示氧原子，Y是碳原子数为1〜4的烷基，卤素原子或腈基，R ^{13 氢原子或甲基，R ^{16 代表氢原子或氟原子，Z是氧或硫原子，R ^{3 和R ^{5 各自独立地为表示α-或β-位置氢原子，R ^{4 和R ^{6 各自独立地为α-或β-位置氢原子，C _{1 -C _{5 烷基，一个C _{1 -C _{5 - 烷氧基，C _{1 -C _{5 酰基，或羟基或芳烷基或烷芳基，R _{3 和R _{4 一起为氧原子，R _{5 和R _{6 一起为氧原子，R ^{7 和R ^{8 各自为氢原子或一起CH _{2 是一个基团，及其药学上可接受的盐，它们的制备和作为药物的雌激素依赖性疾病的预防和治疗为特征的抑制17-Hydroxysteroiddehydro-的使用首先影响脱氢酶类型}}}}}}}}}}}}}}}}}}}}}}}}}}}

7. 发明申请

WO2007071456B1 FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR 审中-公开
标题翻译：荧光素和卡巴索作为EP2受体的配体
公开(公告)号：WO2007071456B1
公开(公告)日：2007-08-23
申请号：PCT/EP2006012640
申请日：2006-12-21
申请人： BAYER SCHERING PHARMA AG , BRAEUER NICO , BUCHMANN BERND , HUWE CHRISTOPH , LINDENTHAL BERNHARD , LANGER GERNOT , PETERS OLAF , SCHUBERT GERD , BOTHE ULRICH , TOSCHI LUISELLA , PETERS-KOTTIG MICHAELE
发明人： BRAEUER NICO , BUCHMANN BERND , HUWE CHRISTOPH , LINDENTHAL BERNHARD , LANGER GERNOT , PETERS OLAF , SCHUBERT GERD , BOTHE ULRICH , TOSCHI LUISELLA , PETERS-KOTTIG MICHAELE
IPC分类号： C07C211/60 , A61K31/21 , A61K31/403 , A61P29/00 , C07D209/88
CPC分类号： C07D209/88
摘要： The present invention relates to carbazoles/fluorenes, to processes for their preparation and to their use for preparing pharmaceutical agents for the treatment of disorders connected to the EP 2 receptor.
摘要翻译：本发明涉及咔唑/芴，其制备方法及其用于制备用于治疗与EP2受体相关的病症的药物的用途。

8. 发明专利

AR054519A1 MODULADORES NO ESTEROIDES DE RECEPTOR DE PROGESTERONA 未知
公开(公告)号：AR054519A1
公开(公告)日：2007-06-27
申请号：ARP060102750
申请日：2006-06-27
申请人： SCHERING AG
发明人： BOTHE ULRICH , DROESCHER PETER , FUHRMANN ULRIKE , HILLISCH ALEXANDER , KAUFMANN GUENTER , SCHMEES NORBERT , SCHWEDE WOLFGANG , SOBEK LOTHAR , MOELLER CARSTEN
IPC分类号： C07D265/02 , C07D413/12 , A61K31/536 , A61P5/34
摘要： Su uso para la preparacion de medicamentos y a las composiciones farmacéuticas que contienen estos compuestos. Los compuestos son apropiados para la terapia y la prevencion de enfermedades ginecologicas, como endometriosis, leiomiomas del utero, sangrados disfuncionales y dismenorrea y para el tratamiento y la prevencion de tumores hormona-dependientes y para el control de la fertilidad femenina, así como para la terapia de sustitucion hormonal. Reivindicacion 1: Compuestos de la formula general (1), caracterizado porque: R1 y R2 representan independientemente uno de otro, un átomo de hidrogeno, un grupo alquilo C1-5 lineal o no-lineal, ramificado o no-ramificado, además, junto con el átomo de C de la cadena forman un anillo con un total de 3-7 miembros; R3 representan un radical C:::C-Ra, donde: Ra es un hidrogeno o es alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, heterocicloalquilo, opcionalmente mono o polisustituido con K, de manera igual o diferentes o significa un arilo o heteroarilo, opcionalmente mono o polisustituido con L, de manera igual o diferente; K significa ciano, halogeno, hidroxilo, nitro, C(O)Rb, CO2Rb, -O-Rb, -S-Rb, SO2NRcRd, -C(O)-NRcRd, -OC(O)-NRcRd, -C=NORb -NRcRd o es cicloalquilo C3-10, heterocicloalquilo, opcionalmente mono o polisustituido con M, de manera igual o diferente o significa arilo o heteroarilo, opcionalmente mono o polisustituido con L; L significa alquilo C1-8, alquenilo C2-8, alquinilo C2-8, perfluoroalquilo C1-6, perfluoralcoxilo C1-6, alcoxiC1-6-alcoxiloC1-6, (CH2)p-cicloalquiloC3-10, (CH2)p-heterocicloalquilo, (CH2)pCN, (CH2)pHal, (CH2)pNO2, (CH2)p-C6-12-arilo, (CH2)p-heteroarilo, -(CH2)pPO3(Rb)2, -(CH2)pNRcRd, -(CH2) pNReCORb, - (CH2)pNReCSRb, -(CH2)pNReS(O)Rb, -(CH2)pNReS(O)2Rb, -(CH2)pNReCONRcRd, -(CH2)pNReCOORb, -(CH2)pNReC(NH)NRcRd, -(CH2)pNReCSNRcRd, -(CH2)pNReS(O)NRcRd, -(CH2)pNReS(O)2NRcRd, -(CH2)pCORb, -(CH2)pCSRb, -(CH2)pS(O)Rb, -(CH2)pS(O)(NH)Rb, -(CH2)pS(O)2Rb, - (CH2)pS(O)2NRcRd, -(CH2)pSO2ORb, -(CH2)pCO2Rb, -(CH2)pCONRcRd, -(CH2)pCSNRcRd, -(CH2)pORb, -(CH2)pSRb, -(CH2) pCRb(OH)-Re, -(CH2)p-C=NORb, -O-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH- o -(CH2)n+2-, donde n = 1 o 2 y los átomos de oxígeno y/o carbono en posicion final están unidos con átomos de carbono del anillo directamente adyacentes; M es alquilo C1-6 o un grupo -CORb, CO2Rb, -O-Rb, o -NRcRd, donde Rb significa un hidrogeno o un grupo alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, arilo C6-12 o perfluoroalquilo C1-3; y Rc y Rd representan independientemente uno de otro un hidrogeno, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, arilo C6-12, C(O)Rb o un grupo hidroxilo, donde cuando: Rc es un grupo hidroxilo, Rd solamente puede ser un hidrogeno, un alquilo C1-C6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10 o arilo C6-12 y viceversa; y Re representa un hidrogeno, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10 o arilo C6- 12; y p puede ser un numero de 0-6; o R3 representa un radical C=C-RgRh, donde: Rg y Rh representan independientemente uno de otro un hidrogeno o un alquilo C1-8, alquenilo C2-C8 o alquinilo C2-C8, opcionalmente mono o polisustituido con X, de manera igual o diferentes, donde X es un ciano, halogeno, hidroxilo, nitro, -C(O)Rb, CO2Rb, -O-Rb, -C(O)-NRcRd, - NRcRd con los significados mencionados más arriba para Rb, Rc y Rd; y R4 es un átomo de hidrogeno, un grupo metilo o etilo o un grupo alquilo C1-3 parcial o totalmente fluorado; A representa un anillo aromático mono- o bicíclico, carbocíclico o heterocíclico, que puede estar opcionalmente mono- o polisustituido con alquilo C1-8, alquenilo C2-8, alquinilo C2-8, perfluoroalquilo C1- 6, perfluoralcoxilo C1-6, alcoxiC1-6- alquiloC1-6, alcoxiC1-6-alcoxiloC1-6, (CH2)p-cicloalquiloC3-10, (CH2)p-heterocicloalquilo, (CH2)pCN, (CH2)pHal, (CH2)pNO2, (CH2)p-ariloC6-12, (CH2)p-heteroarilo; -(CH2)pPO3(Rb)2, -(CH2)pNRcRd, -(CH2)pNReCORb, - (CH2)pNReCSRb, -(CH2)pNReS(O)Rb, -(CH2)pNReS(O)2Rb, -(CH2) pNReCONRcRd, -(CH2)pNReCOORb, -(CH2)pNReC(NH)NRcRd, -(CH2)pNReCSNRcRd, -(CH2)pNReS(O)NRcRd, -(CH2)pNReS(O)2NRcRd, -(CH2) pCORb, -(CH2)pCSRb, -(CH2)pS(O)Rb, -(CH2)pS(O)(NH)Rb, -(CH2)pS(O)2Rb, - (CH2)pS(O)2NRcRd, -(CH2)pSO2ORb, -(CH2)pCO2Rb, -(CH2) pCONRcRd, -(CH2)pCSNRcRd, -(CH2)pORb, -(CH2)pSRb, -(CH2)pCRb(OH)-Rd, -(CH2)p-C=NORb, -O-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH- o -(CH2)n+2-, donde n = 1 o 2 y los átomos de oxígeno y/o carbono en posicion final están unidos con átomos de carbono del anillo directamente adyacentes; o A representa un radical -CO2Rb, C(O)NRcRd, CORb; o A representa un grupo alquenilo-CR5=CR6R7, donde R5, R6 y R7 son iguales o diferentes y representan independientemente uno de otro, átomos de hidrogeno, átomos de halogeno, radicales arilo o un grupo alquilo C1-5 insustituidos o parcial o completamente fluorado; o A representa un grupo alquinilo-C:::R5, con el significado mencionado más arriba para R5; y B representa un grupo carbonilo o CH2, así como sus sales aceptables para uso farmacéutico.

9. 发明专利

DOP2006000150A MODULARES NO ESTEROIDES DE RECEPTORES DE PROGESTERONA 未知
公开(公告)号：DOP2006000150A
公开(公告)日：2006-12-31
申请号：DO2006000150
申请日：2006-06-26
申请人： SCHERING AG
发明人： SCHWEDE WOLFGANG , SCHMMES NORBERT , MOLLER CARSTEN , SCHMIDT ANJA , BOTHE ULRICH , FUHRMANN ULRIKE
摘要： La presente invencion se refiere a moduladores no esteroides del receptor de progesterona de la formula general I, a su use para la preparacion de medicamentos, asi como a las composiciones farmaceuticas que contienen estos compuestos. Los compuestos segun la invencion son apropiados para la terapia y la prevencion de enfermedades ginecologicas tales como endometriosis, leiomiomas de utero, hemorragias disfuncionales y dismenorrea y para la terapia y la prevencion de tumores dependientes de hormonas y para el use para el control de la fertilidad femenina y para la terapia de reemplazo hormonal.

10. 发明专利

PE03372006A1 17ALFA-FLUOROESTEROIDES 未知
公开(公告)号：PE03372006A1
公开(公告)日：2006-05-25
申请号：PE0004212005
申请日：2005-04-15
申请人： SCHERING AG
发明人： BOTHE ULRICH , MENZENBACH BERND , DROESCHER PETER , ELGER WALTER , REDDERSEN GUDRUN , SCHNEIDER BIRGITT , HILLISCH ALEXANDER , SCHWEIKERT HANS-UDO
IPC分类号： A61K31/56 , A61P5/24 , A61P35/00 , C07J7/00 , C07J41/00 , C07J75/00
CPC分类号： C07J41/0038
摘要： REFERIDA A UN COMPUESTO 17 ALFA-FLUOROESTEROIDE DE FORMULA I, DONDE R1 ES H O METILO; R2 Y R3 SON H, Cl, METILO; ENTRE LOS CARBONOS 6 Y 7 PUEDE HABER UNA UNION SIMPLE O DOBLE Y ENTRE LOS CARBONOS 9 Y 10 PUEDE HABER UNA UNION SIMPLE O DOBLE. ES COMPUESTO PREFERIDO (E)-17ALFA-FLUORO-3-OXO-ESTR-4-EN-17BETA-CARBALDEHIDOXIMA. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN A DICHO COMPUESTO, EL CUAL ES GESTAGENO E INHIBIDOR DE LA 5 ALFA-REDUCTASA, POR LO QUE ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DE CIERTOS ORGANOS Y TEJIDOS, TANTO EN EL HOMBRE COMO EN LA MUJER, COMO CONSECUENCIA DE UN NIVEL AUMENTADO DE ANDROGENOS, TALES COMO ACNE, HIRSUTISMO, ALOPECIA, ENTRE OTRAS

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式